Anti-CAPS Antibody (R3T03)

Catalog No.

RHG67501

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a

Clonality

Monoclonal

Tested applications

IHC: 1:500-1:1000, IP: 1:100-1:200, WB: 1:500-1:1000

Target

Calcyphosin, CAPS, Calcyphosine

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q13938

Applications

IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% Sodium Azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

R3T03

IL-18 inhibition enlarges lesions, necrotic cores and thickens fibrous caps in Jak2 V617F clonal hematopoiesis-driven atherosclerosis., PMID:40501724

Catastrophic Antiphospholipid Syndrome Following Treated Antineutrophilic Cytoplasmic Antibody (ANCA) Vasculitis: Unusual Case Presentation., PMID:40486372

Complex presentation of probable catastrophic antiphospholipid syndrome: diagnostic dilemmas and treatment strategies., PMID:40484440

Association of cancer and anti-synthetase syndrome: a retrospective multicentre study., PMID:40460913

Primary Catastrophic Antiphospholipid Syndrome With Multiple Infarcts in the Kidney, Liver, and Spleen in a Healthy Young Man: A Case Report., PMID:40322451

Case Report: Primary adrenal insufficiency due to bilateral adrenal infarction and antiphospholipid syndrome in Covid19 - A complicate case of cardiogenic shock., PMID:40241990

Coronavirus disease 2019 and catastrophic antiphospholipid syndrome: Case report., PMID:40153768

Catastrophic antiphospholipid syndrome presenting with a stroke as a first presentation: case report., PMID:40124700

Multi-centered clinical validation demonstrating superior precision in lupus diagnosis: T cell autoantibodies and TC4d outperform conventional lupus erythematosus biomarkers., PMID:40093011

An atypical presentation of catastrophic antiphospholipid syndrome with refractoriness to treatment., PMID:39973823

Directed evolution of an orthogonal transcription engine for programmable gene expression in eukaryotes., PMID:39811667

Case Report: Catastrophic antiphospholipid syndrome in a pediatric patient after percutaneous treatment of aortic re-coarctation., PMID:39764168

Dual-Enzyme-Instructed Peptide Self-Assembly to Boost Immunogenic Cell Death by Coordinating Intracellular Calcium Overload and Chemotherapy., PMID:39754594

Case Report: Primary catastrophic antiphospholipid syndrome in a pediatric patient with cerebral venous sinus thrombosis as the first manifestation., PMID:39722765

Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody-drug conjugates by specific hinge fragmentation-liquid chromatography., PMID:39688670

Catastrophic antiphospholipid syndrome of pregnancy with acute massive cerebral infarction: A case report., PMID:39686499

The evaluation of DNA-linked inhibitor antibody and AlphaScreen assays for high-throughput screening of compounds targeting the cap-binding domain in influenza a polymerase., PMID:39674552

Development and application of an uncapped mRNA platform., PMID:39648715

Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease., PMID:39644034

Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316

Seronegative Catastrophic Antiphospholipid Syndrome: A Case Report of a Deadly Diagnosis., PMID:39493117

Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices., PMID:39429267

Directed evolution of an orthogonal transcription engine for programmable gene expression in eukaryotes., PMID:39386662

Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing., PMID:39381601

Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases., PMID:39355252

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China., PMID:39334417

Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome., PMID:39318635

Antiphospholipid Syndrome and Catastrophic Antiphospholipid Syndrome: A Comprehensive Review of Pathogenesis, Clinical Features, and Management Strategies., PMID:39252716

Catastrophic antiphospholipid syndrome: Lessons from the "CAPS Registry"., PMID:39174151

Selective inhibition of interleukin 6 receptor decreased inflammatory cytokines and increased proteases in an experimental model of critical calvarial defect., PMID:39166608

Catastrophic Antiphospholipid Syndrome: A Life-Threatening Condition., PMID:39130941

Redesigning amino/carboxyl ends of DARPin G3 for high thermostability and production in tobacco transplastomic plants., PMID:39126530

Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies., PMID:39096716

Hematological features and alternate diagnoses in critically ill thrombotic antiphospholipid syndrome patients., PMID:39073513

Systemic Embolism Following Mechanical Thrombectomy for Acute Ischemic Stroke: A Case of Suspected Catastrophic Antiphospholipid Syndrome., PMID:39040914

Refining treat-to-target strategies in cryopyrin-associated periodic syndromes: the role of inflammatory markers., PMID:38970372

Coexistence of systemic sclerosis and cryopyrin-associated periodic syndrome., PMID:38940218

Histologic Analysis of 'Distraction Vaginogenesis' in a Rat Model., PMID:38921727

NLRP3 Inflammasome in Autoinflammatory Diseases and Periodontitis Advance in the Management., PMID:38882867

Triumph Over Adversity: A Comprehensive Case Series on Successful Pregnancy Outcomes in Antiphospholipid Antibody (APLA)-Positive Patients., PMID:38803763

Pediatric catastrophic antiphospholipid syndrome with extensive skin involvement., PMID:38783589

Some mechanistic underpinnings of molecular adaptations of SARS-COV-2 spike protein by integrating candidate adaptive polymorphisms with protein dynamics., PMID:38713502

Management of Anticoagulation and Antifibrinolytics in Catastrophic Antiphospholipid Syndrome., PMID:38705843

Trem2 Agonist Reprograms Foamy Macrophages to Promote Atherosclerotic Plaque Stability-Brief Report., PMID:38695172

Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?, PMID:38652403

Antiphospholipid syndrome in the era of COVID-19 - Two sides of a coin., PMID:38604461

Cardiac involvement in the catastrophic antiphospholipid syndrome (CAPS): Lessons from the "CAPS registry"., PMID:38552300

Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria., PMID:38534211

Impact of Methylthioxylose Substituents on the Biological Activities of Lipomannan and Lipoarabinomannan in Mycobacterium tuberculosis., PMID:38511206

Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome., PMID:38442982

Document Download

Anti-CAPS Antibody (R3T03).pdf